FDA Approves Trastuzumab Biosimilar to Treat Forms of HER2-Overexpressing Cancer

Trastuzumab is indicated for adjuvant breast cancer, metastatic breast cancer, and gastric cancer.

Related Keywords

Chrys Kokino ,Fam Trastuzumab Deruxtecan Nxki ,Daiichi Sankyo ,Us Food Drug Administration Approval ,Astrazeneca ,Accord Biopharma Inc ,Accord Biopharma ,Drug Administration Approval ,Several Forms ,Locally Advanced ,Metastatic Breast ,Positive Solid ,